In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Editorial Advisory Board
Ask The Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Guidelines for Contributors
Report Store
UsernamePublicRestriction
Tags:
Gene Therapy Regenerative Medicine Deals

Gene Therapy Companies Among Top M&A Targets In 2020

Novo Nordisk And Gilead Tipped To Spend

  • Analysis

Executive Summary

Zolgensma shows that a gene therapy can be a commercial hit – but there is still plenty to be wary of in this cutting-edge field.

You may also be interested in...



A Decade’s Deals In Indian Pharma Point To 2020 Trends

A look at corporate acquisitions and private equity deals in the Indian pharmaceutical industry over 2010-2019 reveals some trends, lessons and targets for possible activity in 2020.

After Real-World Data Row, AZ Looks To NHS England For Tagrisso Deal

Tagrisso has become AstraZeneca’s oncology flagship product, but cannot secure frontline use in England.

Tecentriq Disappoints In Post-Surgery Bladder Cancer

Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
Table

View full table

Topics

Related Companies

Tags:
Gene Therapy Regenerative Medicine Deals
UsernamePublicRestriction

Register

IV124415

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By